Business Context and Reporting Period
This Form 8-K Current Report from Atyr Pharma, Inc. covers events occurring on May 15, 2018, specifically the Company's 2018 Annual Meeting of Stockholders. The filing details the departure of a director, the election of new directors, the ratification of the independent auditor, and the approval of a significant equity conversion.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure events rather than financial performance metrics.
Material Changes and Corporate Actions
- Director Departure: Srinivas Akkaraju, M.D., Ph.D., completed his term as a Class III director and did not stand for reelection. The filing states this decision was not due to any disagreement with management.
- Director Elections: Stockholders elected two new Class III directors, Jeffrey S. Hatfield and Sanjay S. Shukla, M.D., M.S., to serve until the 2021 Annual Meeting.
- Equity Conversion: Stockholders approved the issuance of 11,429,760 shares of common stock upon the conversion of 2,285,952 shares of Class X Convertible Preferred Stock.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Voting Results and Shareholder Participation
Of the 29,797,663 shares entitled to vote, 20,783,989 were present or represented by proxy. All proposals were approved.
| Proposal | Votes For | Votes Against | Abstentions |
|---|---|---|---|
| Election of Jeffrey S. Hatfield | 12,220,027 | 4,469,651 (Withheld) | N/A |
| Election of Sanjay S. Shukla | 16,556,842 | 132,836 (Withheld) | N/A |
| Ratification of Ernst & Young LLP | 20,680,864 | 45,053 | 58,072 |
| Approval of Preferred Stock Conversion | 14,877,522 | 1,810,899 | 1,257 |
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The only risk-related disclosure notes that the departing director's exit was not the result of a disagreement with the Company.
Key Facts for Investor Verification
- Verify the impact of the issuance of 11.4 million new common shares on existing shareholder dilution.
- Confirm the composition of the Board of Directors following the election of Messrs. Hatfield and Shukla.
- Review the Company's Proxy Statement filed on April 3, 2018, for detailed biographies of the new directors and further context on the preferred stock conversion.